Aleksandra Barańska
ID
Aleksandra Maziarz
ID
 Email src
Jacek Roliński
ID
Janusz Klatka
ID
Katarzyna Dudzińska-Ćwiek
ID
Jacek Tabarkiewicz
ID
 Email src
Chair and Department of Clinical Immunology, Medical University of Lublin, Lublin, Poland
Institute of Experimental and Clinical Medicine, Department of Immunology, Faculty of Medicine, University of Rzeszow, Rzeszow, Poland
Chair and Department of Clinical Immunology, Medical University of Lublin, Lublin, Poland
Chair and Department of Otolaryngology and Laryngological Oncology, II Faculty of Medicine with English Language Division, Medical University of Lublin, Lublin, Poland
Chair and Department of Otolaryngology and Laryngological Oncology, II Faculty of Medicine with English Language Division, Medical University of Lublin, Lublin, Poland
Department of Human Immunology, Institute of Medical Sciences, Medical College, University of Rzeszow, Rzeszow, Poland
Received: 11 December 2018 / Accepted: 5 February 2019 / Published: 30 March 2019

Abstract

Introduction. Laryngeal squamous cell carcinoma (LSCC) is a common type of head and neck malignancy. Because of unsatisfactory results of therapy, development of new strategies for LSCC treatment is needed. It is believed that heat shock protein 70 (HSP70) is involved in pathogenesis of LSCC. Thus, targeting HSP70 seems to be promising strategy for laryngeal cancer treatment.

Aim. The aim of the study was to assess the HSP70 concentration in laryngeal squamous cell carcinoma specimens and its correlation with tumor volume and TNM staging.

Material and methods. An ELISA method and a Bradford protein assay were used to evaluate the HSP70 concentration in peripheral blood cells, tumor tissue and lymph nodes from the patients suffering from LSCC.

Results. We demonstrated that the HSP70 concentration is significantly different between examined compartments. The highest level was observed in peripheral blood, while the lowest was in the lymph nodes. The HSP70 expression was correlated to tumor volume.

Conclusion. Our results showed varied expression of HSP70 in tissue from patients with LSCC, but there was no association between HSP70 concentration and TNM staging. Currently, application of HSP70 inhibition as a LSCC treatment could be rather associated with systemic blocking of this molecule than target inhibition in tumor tissue. However, further analysis on a larger group of patients is needed. 

 

Cite

Barańska A, Maziarz A, Roliński J, Klatka J, Dudzińska-Ćwiek K, Tabarkiewicz J. Expression of heat shock protein 70 in the tissue of patients with laryngeal squamous cell carcinoma. Eur J Clin Exp Med. 2019;17(1):16–21. doi: 10.15584/ejcem.2019.1.3

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited